BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28459197)

  • 21. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
    Sone K; Oguri T; Nakao M; Kagawa Y; Kurowaka R; Furuta H; Fukuda S; Uemura T; Takakuwa O; Kanemitsu Y; Ohkubo H; Takemura M; Maeno K; Ito Y; Sato H; Muramatsu H; Niimi A
    Anticancer Res; 2017 Feb; 37(2):935-939. PubMed ID: 28179355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated lactic acid is a negative prognostic factor in metastatic lung cancer.
    Vlachostergios PJ; Oikonomou KG; Gibilaro E; Apergis G
    Cancer Biomark; 2015; 15(6):725-34. PubMed ID: 26406401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer.
    Qian Q; Zhan P; Yu L; Shi Y; Cheng J; Wei S; Wang Q; Song Y
    Clin Lung Cancer; 2011 Mar; 12(2):131-7. PubMed ID: 21550560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The value of plasma netrin-1 in non-small cell lung cancer patients as diagnostic and prognostic biomarker.
    Yıldırım ME; Kefeli U; Aydın D; Sener N; Gümüş M
    Tumour Biol; 2016 Sep; 37(9):11903-11907. PubMed ID: 27067437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
    Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
    Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
    Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
    Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
    Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
    Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer.
    Liu Y; Zhang G; Li H; Han L; Fu A; Zhang N; Zheng Y
    Biomed Pharmacother; 2015 Oct; 75():185-90. PubMed ID: 26337230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
    Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
    J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.
    Thöm I; Andritzky B; Schuch G; Burkholder I; Edler L; Johansen JS; Bokemeyer C; Schumacher U; Laack E
    Cancer; 2010 Sep; 116(17):4114-21. PubMed ID: 20564116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of Epidermal Growth Factor Receptor Mutations in Serum Among Japanese Patients Treated With First-Line Erlotinib for Advanced Non-Small-Cell Lung Cancer.
    Nishio M; Goto K; Chikamori K; Hida T; Katakami N; Maemondo M; Ohishi N; Tamura T
    Clin Lung Cancer; 2016 Jan; 17(1):24-9.e1. PubMed ID: 26336854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
    Fiala O; Pesek M; Skrickova J; Kolek V; Salajka F; Tomiskova M; Satankova M; Kultan J; Kuliskova J; Svaton M; Hrnciarik M; Hejduk K; Chloupkova R; Topolcan O; Hornychova H; Nova M; Ryska A; Finek J
    Tumour Biol; 2017 Feb; 39(2):1010428317691186. PubMed ID: 28218046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of the serum crosslinked N-telopeptide of type I collagen as a prognostic marker for non-small-cell lung cancer.
    Tamiya M; Kobayashi M; Morimura O; Yasue T; Nakasuji T; Satomu M; Kohei O; Takayuki S; Morishita N; Suzuki H; Sasada S; Okamoto N; Hirashima T; Kawase I
    Clin Lung Cancer; 2013 Jan; 14(1):50-4. PubMed ID: 22609050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
    Nygaard AD; Garm Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Lung Cancer; 2013 Mar; 79(3):312-7. PubMed ID: 23238036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum nectin-2 levels are diagnostic and prognostic in patients with colorectal carcinoma.
    Karabulut M; Gunaldi M; Alis H; Afsar CU; Karabulut S; Serilmez M; Akarsu C; Seyit H; Aykan NF
    Clin Transl Oncol; 2016 Feb; 18(2):160-71. PubMed ID: 26184725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Periostin, a matrix protein, has potential as a novel serodiagnostic marker for cholangiocarcinoma.
    Fujimoto K; Kawaguchi T; Nakashima O; Ono J; Ohta S; Kawaguchi A; Tonan T; Ohshima K; Yano H; Hayabuchi N; Izuhara K; Sata M
    Oncol Rep; 2011 May; 25(5):1211-6. PubMed ID: 21347516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification.
    Lee HJ; Choe G; Jheon S; Sung SW; Lee CT; Chung JH
    J Thorac Oncol; 2010 May; 5(5):649-57. PubMed ID: 20354454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer.
    Zhang Z; Xiao Y; Zhao J; Chen M; Xu Y; Zhong W; Xing J; Wang M
    Respirology; 2016 Apr; 21(3):519-25. PubMed ID: 26661896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer.
    Gregorc V; Ceresoli GL; Floriani I; Spreafico A; Bencardino KB; Ludovini V; Pistola L; Mihaylova Z; Tofanetti FR; Ferraldeschi M; Torri V; Cappuzzo F; Crinò L; Tonato M; Villa E
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6006-12. PubMed ID: 15447984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.